Abstract:Background: Various cancer types have been studied and understood using long noncoding RNA (lncRNA). Despite this, only a few studies have examined anoikis-related lncRNAs in kidney renal clear cell carcinoma (KIRC). As a result, this study evaluated a powerful prognostic model for KIRC patients based on anoikis-lncRNAs and identified potential biological targets. Methods: Anoikis-related lncRNAs associated with patient prognosis were identified using Pearson correlation, variance, and univariate Cox regression analyses. A predictive model that incorporated 4 anoikis-related lncRNAs has been constructed using the least absolute shrinkage and selection operator (LASSO) regression algorithm. The prognostic performance of the proposed model has also been assessed utilizing Kaplan-Meier (KM) survival and receiver operating characteristic (ROC) curve analyses. An ESTIMATE analysis was carried out on the low- as well as high-risk subtypes to evaluate immune cell infiltration status. Furthermore, CIBERSORT, TIMER, and QUANTISEQ along with other algorithms were applied for determining the infiltration status of numerous immune cells across both groups. In addition, immune checkpoint gene expression in both groups was also determined. Finally, drug sensitivity assays and in vitro experiments were performed to validate the results. Results: A total of sixty-three lncRNAs associated with anoikis and KIRC prognosis were identified via univariate cox analysis, and four lncRNAs (Z99289.2, AC084876.1, LINC00460, and AC090337.2.) were selected as hub lncRNAs. A prognostic signature has been developed based on the expression levels and coefficiency of these four lncRNAs while establishing its efficacy in part and whole TCGA KIRC cohort. Furthermore, by using this risk signature, high- as well as low-risk KIRC patients could be distinguished more precisely it can predict patient outcomes as well. The survival predictions by the nomogram exhibited an absolute degree of concordance with actual situations. In vitro experiments verified that LINC00460 downregulation contributed to the growth inhibition of KIRC cell lines and promoted apoptosis of cancer cells. method: Anoikis-related lncRNAs associated with patient prognosis were identified using Pearson correlation, variance, and univariate Cox regression analyses. A predictive model that incorporated 4 anoikis-related lncRNAs has been constructed using the least absolute shrinkage and selection operator (LASSO) regression algorithm. The prognostic performance of the proposed model has also been assessed utilizing Kaplan-Meier (KM) survival and receiver operating characteristic (ROC) curve analyses. An ESTIMATE analysis was carried out on the low- as well as high-risk subtypes to evaluate immune cell infiltration status. Furthermore, CIBERSORT, TIMER, and QUANTISEQ along with other algorithms were applied for determining the infiltration status of numerous immune cells across both groups. In addition, immune checkpoint gene expression in both groups was also determined. Finally, drug sensitivity assays and in vitro experiments were performed to validate the results. Conclusion: This study suggests that anoikis-related lncRNAs could serve as valuable prognostic markers for KIRC. Additionally, they may provide insight into future KIRC treatment options by reflecting on the situation of the kidney immune microenvironment. result: A total of sixty-three lncRNAs associated with anoikis and KIRC prognosis were identified via univariate cox analysis, and four lncRNAs (Z99289.2, AC084876.1, LINC00460, and AC090337.2.) were selected as hub lncRNAs. A prognostic signature has been developed based on the expression levels and coefficiency of these four lncRNAs while establishing its efficacy in part and whole TCGA KIRC cohort. Furthermore, by using this risk signature, high- as well as low-risk KIRC patients could be distinguished more precisely it can predict patient outcomes as well. The survival predictions by the nomogram exhibited an absolute degree of concordance with actual situations. In vitro experiments verified that LINC00460 downregulation contributed to the growth inhibition of KIRC cell lines and promoted apoptosis of cancer cells.

Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer

Identification of anoikis-related lncRNAs and analysis of immune infiltration in patients with breast cancer

Identification of Necroptosis-Related Long Noncoding RNAs for Immunotherapy Selection and Prognosis Prediction in Patients with Colorectal Cancer

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

Anoikis-Related Long Non-Coding RNA Signatures to Predict Prognosis and Immune Infiltration of Gastric Cancer

Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer

Identification and Experimental Validation of Immune-Associate Lncrnas for Predicting Prognosis in Cervical Cancer

Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy

Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma

Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification

Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma

Construction and Validation of a Seven Anoikis-Related lncRNA Risk Model for Breast Cancer

Development and Validation of Anoiki-Related Lncrna Signature Prediction Model for KIRC Prognosis

Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma

Construction of anoikis-related lncRNAs risk model: Predicts prognosis and immunotherapy response for gastric adenocarcinoma patients

Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma

Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer

Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer

Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

Anoikis-related mRNA-lncRNA and DNA methylation profiles for overall survival prediction in breast cancer patients